Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

January 26, 2024

Time Posted:2025-04-24 14:18

A novel inhaled anti-IL-4Rα monoclonal antibody has been introduced. This drug is also used to treat respiratory diseases such as asthma and COPD. Phase I clinical trials of the anti-IL-4Rα monoclonal antibody have been completed, and Phase II clinical trials have begun.

November 2023

Time Posted:2025-04-24 14:18

Introducing a highly selective second-generation Nav1.8 inhibitor, an innovative drug for pain treatment, expected to be highly effective and non-addictive. Health Yuan is responsible for subsequent clinical research and application for production of this drug.

November 2023

Time Posted:2025-04-24 14:18

Acquired rights to an anti-TSLP monoclonal antibody, a drug used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The anti-TSLP monoclonal antibody is currently undergoing Phase II clinical trials for asthma in China.

April 2023

Time Posted:2025-04-24 14:18

An exclusive license agreement for a new antiviral drug against influenza in Greater China has been reached. The new drug was submitted for production in August and is expected to be launched next year.

Health Spring: Resilience in Exchange for Elasticity

Time Posted:2025-04-16 13:15

It's time to test resilience! On one hand, there is downward pressure from the complex market, policy environment, and the transformation of the pharmaceutical industry; on the other hand, there is the upward opportunity of AI technology deeply empowering pharmaceutical companies to accelerate innovation. After a period of collective downturn, Chinese pharmaceutical companies are entering a stage of "structural" differentiation.

In 2024, how did Health Yuan answer the "three philosophical questions of life"?

Time Posted:2025-04-11 16:11

In 2024, how did Health Yuan answer the "three philosophical questions of corporate existence"? 2025-04-08 16:23 · Serious Finance Socrates' famous sayings, "Who am I?", "Where do I come from?", "Where am I going?", are three questions about life. For a company, especially a listed company, the questions of corporate existence cannot be avoided: "What kind of company is this?" "Where does the company's money come from?" "Where does the company's money go?"

Jiankangyuan's 2024 revenue reached 15.6 billion yuan. The company achieved a comprehensive breakthrough in innovative respiratory drugs and actively embraced AI technology.

Time Posted:2025-04-08 11:22

On the evening of April 7, Jiankangyuan released its 2024 annual report, showing annual operating revenue of 15.619 billion yuan, net profit attributable to shareholders of 1.387 billion yuan, net profit attributable to shareholders after deducting non-recurring gains and losses of 1.319 billion yuan, and net cash flow from operating activities of 3.636 billion yuan.

Health Yuan: PREP inhibitor breakthroughs in COPD treatment bottlenecks, innovative drugs to help public health

Time Posted:2025-04-02 13:25

With the increasing number of COPD (Chronic Obstructive Pulmonary Disease) patients globally, existing treatments face the dual challenges of efficacy and compliance. COPD is one of the leading causes of respiratory failure and death worldwide, and while existing treatments have made progress, they still fail to effectively address issues such as acute exacerbations and prolonged disease progression in patients. HealthGen Biotech, through technological innovation, is developing a PREP inhibitor. This breakthrough product will bring new hope to COPD patients while driving progress and development in the global COPD treatment field.

< 1234...55 >